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and T.E. Starzl 
H EPATIC allografts are more resistant than other solid 
organs to antibody-mediated rejection, and human 
hepatic transplants can be successfully performed in the 
face of donor-specific lymphocytotoxic antibodies (posi-
tive crossmatch).1.2 However, we recently reported a 
significant decrease in patient and graft survival when a 
liver transplant was performed against a positive IgG 
lymphocytotoxic crossmatch.3 Grafts that did or did not 
fail had histopathologic findings mimicking preservation 
injury, although specific deposits of immunoglobulins and 
complement were rarely found. 4 These data suggest that 
lymphocytotoxic antibodies can have a deleterious effect 
in liver transplantation. even if they do not precipitate 
hyperacute rejection. 
Complement plays a crucial role in the pathophysiology 
of antibody-mediated rejection. We therefore prospec-
tively analyzed total complement activity and detection of 
circulating immune complexes in primary liver allograft 
recipients with positive IgG lymphocytotoxic antibodies. 
The objective was to determine if in allosensitized patients 
complement consumption (low peripheral blood levels) 
was reflective of an antibody-mediated reaction. Because 
low peripheral complement levels may be a result of 
consumption or poor production, the crossmatch positive 
patients were compared with a control group of cross-
match negative primary liver allograft recipients with se-
vere hepatocellular damage. 
MATERIALS AND METHODS 
Between March I. 1991. and December 31. 1991. 22 consecutive 
adult patients received a liver from an IgG lymphocytotoxic 
positive crossmatch donor (more than 50% of donor lymphocytes 
were killed by dithiothreitol [Om-pretreated recipient serum), 
and were prospectively followed during the first month after 
transplantation. A group of 10 patients with negative crossmatch 
and severe hepatocellular damage, assessed by elevation of trans-
aminase (ASn above 2500 UlmL on day I posttransplant. served 
as controls.' 
Immunosuppression 
Standard postoperative immunosuppression consisted of FK 506 
and low-dose steroids. FK 506 was initially given in a continuous 
IV infusion at 0.1 mg/kg/d. which was converted to an oral dose of 
0.15 mg/kg every 12 hours with the return of bowel function. 
Subsequent dosage adjustments were guided by the quality of the 
graft. the presence of rejection, toxicity. and the FK 506 plasma 
trough level (normal value <2 ng/mL). Rejection episodes were 
treated with either 1 g bolus of methylprednisolone or a recycling 
of high-dose steroids starting at 200 mg and tapering to 20 mg over 
5 days. If rejection persisted, a 3 to 5-day course of 5 to 10 mg/d 
of OKTI was given. 
Treatment With Prostaglandin E1 (PGE1) 
Fourteen patients with positive crossmatch and all the patients 
with hepatocellular damage received treatment with PGE1 (Pros-
tin VRR) 0.2 to 0.6 JLg/kglh IV during 5 to 7 days after transplan-
tation. 
Crossmatch Test 
Pretransplant sera were drawn immediately before liver transplan-
tation and used for the crossmatching. All sera were orr treated 
to inactivate IgM. The donor T lymphocytes were isolated from 
lymph nodes using C03-conjugated dynabeads. The cytotoxicity 
test was performed according to National Institutes of Health 
(NIH) standards with one washing. Briefly. 1 ILL of 2 x 1 W/mL T 
lymphocytes were added to I ILL of serum. which was twofold 
diluted up to 1:8 using RPMI 1640 solution, for 1 hour at room 
temperature. After one washing, 5 ILL of rabbit complement was 
added for an additional 1 hour at room temperature and trypan 
blue was added to stain dead cells. 
Total Complement Activity Test 
The method is based on the ability of complement to lyse red 
blood cells. In summary. serum to be tested is placed in wells and 
diffuses radially through an agarose gel containing standardized 
sheep erythrocytes sensitized with hemolysin. An estimate of 
total complement activity (CH lOo) is made by comparison of the 
extent of lysis caused by the serum sample and that caused by 
reference sera run simultaneously. Results are given in UlmL 
(normal value >60 UlmL). 
Detection of Circulating Immune Complexes 
Circulating immune complexes were detected qualitatively using 
zonal electrophoresis on agarose gels.6 
Statistical Analysis 
Repeated measures one-way analysis of variance (ANOV A) was 
used to compare the average complement levels across the time. 
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Table 1. IgG Lymphocytotoxlc Crossrnatch PosHlve cases and Crollrnatch Negative Control. WHh Hepatocellular Damage 
Positive Negative 
Crossmatch Crossmatch P 
Number of pallents 
Age' 
Malelfemale 
Cold ischemic time (h)' 
Panel reactive antibody (%)* 








46.8 ± 13.0 
7/15 
12.0 ± 4.6 
80.0 ± 29.3 
1434.2 ± 1039.6 
17 
7 
Table 1 shows the circumstances of 22 patients with 
positive crossmatch and 10 patients with negative cross-
match and hepatocellular damage. 
Crossmatch After Liver Transplantation 
In 14 of the 22 patients with a positive pretransplant 
crossmatch repeat crossmatch testing 1 day after liver 
transplantation became negative. However. eight patients 
persistently tested positive for donor-specific Iymphocyto-
toxic antibodies after transplantation. The positive cross-
match persisted positive for 4 weeks in five patients and for 
3 weeks in two patients. One patient was retransplanted on 
day 2, and the cross match became negative thereafter. 
Survival 
Four of eight patients (50%) with persistently positive 
crossmatches after transplantation died at an interval of 36 
to 120 days following transplantation. The cause of death 
was sepsis in three patients and respiratory arrest in one. 
Two of 14 patients (14%) whose crossmatch became 
negative died at days 44 and 45 following transplantation 
because of sepsis. No patient with a negative crossmatch 
died. Four of eight grafts (50%) with persistent positive 
crossmatch failed at an interval of 2 to 43 days following 
transplantation. No graft failures occurred in patients 
whose crossmatch became negative after transplantation. 
Of 10 grafts with a negative pre transplant crossmatch and 
hepatocellular damage one failed at day 15 after transplan-
tation. All four patients with persistent positive cross-
match whose graft did not fail received treatment with 
PEG,. In contrast only one of these patients whose graft 
failed received treatment with PEGI' Nine of the 14 
patients whose crossmatch became negative received 
treatment with PEG I' 
Total Complement Activity (CH,co) 
In patients with persistent positive crossmatch after trans-
plantation the median CH lOo levels at weeks 1,2,3, and 4 
were 24 U/mL (range 19 to 39), 23 UlmL (range 19 to 27), 
10 NS 
53.5 ± 13.5 NS 
614 NS 
13.3 ± 3.9 NS 
3.5 ± 1.7 <.001 
6093.7 ± 3699.5 <.001 
7 NS 
3 NS 
32 U/mL (range 23 to 45), and 25 UlmL (range 19 to 76), 
respectively (NS). In patients whose crossmatch became 
negative after transplantation the median CHICO levels 
were 42 U/mL (range 26 to 77), 65 UlmL (range 53 to 108), 
93 U/mL (range 66 to 150), and 100 U/mL (range 72 to 110) 
at weeks 1.2,3, and 4. respectively (P < .(01). In patients 
with negative cross match and hepatocellular damage the 
median CHICO levels were 67 U/mL (range 28 to 90), 109 
U/mL (range 49 to 165), 106 U/mL (range 72 to 146), and 
125 UlmL (range 79 to 165) (P < .(01) (Fig 1). 
Immune Complex Detection 
As Fig 2 shows. circulating immune complexes were 
detected on weeks I. 2, and 3 in all patients with persis-
tently positive crossmatches. In contrast, circulating im-
mune complexes were detected on weeks I, 2, and 3 in 
50%, 33%, and 30%, respectively, of patients whose 
crossmatch became negative (P < .05). In those patients 
with hepatocellular damage immune complexes were de-






FIg 1. Median complement levels In liver transplant recipients 
with positive IgG Iymphocytotoxic crossmatch pre- and posttrans-
plantation (A), positive pretransplant that became negative post-
transplant (8). and crossmatch negative controls with severe 





Fig 2. Immune complexes detection in liver transplant recipients 
with positive IgG Iymphocytotoxic crossmatch pre and posttrans· 
plantation (A). positive crossmatch pretransplant that became 
negative posttransplant (8). and crossmatch negative controls 
with severe hepatocellular damage (C). 
tected in 20%, 20%, and 33% on weeks 1, 2, and 3, 
respectively (P < .01). On week 4, circulating immune 
complexes were detected in 67% of patients with persistent 
positive crossmatch, 33% of patients whose crossmatch 
became negative, and 20% of patients with hepatocellular 
damage. 
DISCUSSION 
Two different patterns were seen in patients with specific 
antidonor IgG lymphocytotoxic antibodies receiving a 
hepatic allograft. In about 65% of cases, antibodies disap-
peared immediately after transplantation. The outcome of 
these patients did not differ from those with negative 
crossmatch. However, in about 35% of cases antibodies 
persisted after transplantation for a variable interval, usu-
ally longer than 1 month. The outcome of these patients 
was poor. with a 50% graft loss and 50% mortality. The use 
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of POE, was associated with an improvement in the 
outcome of these patients. 
A decrease in total comolement activity and detection of 
circulating immune complexes were observed during 
weeks 1. 2. and 3 following transplantation in patients with 
persistently positive crossmatches in contrast to patients 
whose crossmatch became negative and patients with 
hepatocellular damage. This suggests that a humoral anti-
body-mediated reaction occurred in those patients. How-
ever, graft failure, if it occurs, is usually delayed in 
contrast with kidney or heart allografts. 
We postulate that after graft unclamping the humoral 
reaction develops in patients with preformed lymphocyto-
toxic antibodies. In several cases the new liver graft may 
neutralize the antibodies by various mechanisms. In other 
cases the protective mechanisms are overwhelmed and 
antibodies persist, and humoral reaction continues after 
transplantation. In both cases the dual blood supply is an 
important advantage and likely the most important factor 
to avoid graft failure. The microvascular thrombosis and 
intense vasoconstriction associated with humoral events 
only occur in the arterial tree. Monitoring complement 
activity and circulating immune complex may be useful to 
distinguish patients with persistent antibodies after trans-
plantation. This would permit an adjustment of therapy in 
this high-risk population, particularly the use of PGE, 
which seems to improve the outcome. 
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